Ketorolac is a strong pain reliever used to treat moderate to severe pain, often after surgery or injury. It works quickly to reduce pain and inflammation without being an opioid.[1] Toradol is currently being investigated across 25 indications[3], with its most advanced program in Phase 3.[1]
Toradol is one of 400 small molecule programs targeting Ketorolac. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
744 competitors in Breast Cancer
Toradol
Lexiscan
Voltaren
Zolymbus
Blenoxane
Methylthioninium Chloride
MS Contin
Duragesic-100
MS Contin
Spravato
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details